France Defends Netanyahu Airspace Clearance Despite ICC Warrant 
US Backs Musk in Fight Against EU’s €120 Million X Fine 
US Appeals Court Upholds Anthropic AI Supply Chain Ban 
Brazil Court Suspends Sigma Lithium Mine Operations 
Sara Duterte Posts Bail Over Grave Threats Case 
Colombia Extradites FARC Dissident Leader ‘Spider’ to US 
Canadian Dollar Faces Pressure as Fed-BoC Policy Gap Widens 
Venezuela Nears Deal to Move $4 Billion in Gold to New York Fed 
Paramount Skydance Faces $30 Million Film Penalty in Warner Bros. Deal 
SEC Seeks ISS Client Voting Records in Proxy Adviser Probe 
Japanese Bank Stocks Surge as Bond Yields Fuel Rate Hike Bets 
Fed’s Hammack Says Bond Yield Surge Is Not Driven by Inflation Fears 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
Gold Holds Near $4,275 as Rising Treasury Yields Fuel Fed Rate Hike Bets 
ICE Agent Arrested in Minneapolis Over Venezuelan Man Shooting 
Gold Prices Fall as Treasury Yields Rise on Fed Rate Hike Bets 
LVMH-Hermès Dispute Deepens Over Secret 2002 Share Deal 
Add as a preferred source on Google
Johnson & Johnson disclosed that it spent $800 million in settling "substantially all" of the roughly 9,000 cases by men who claimed having developed excessive breast tissue in using the company's antipsychotic drug Risperdal.
The company said it reached the agreement with lawyers handling the cases, including a lawsuit in Philadelphia by Maryland resident Nicholas Murray, who was awarded an $8 billion in punitive damage by a jury award in 2019. A judge has since reduced the award to $6.8 million.
The lawsuits, filed in Pennsylvania, California, and Missouri, generally accused J&J of failing to warn of the risk called gynecomastia associated with Risperdal, which they claimed were marketed for off-label, unapproved uses with children.
The company denied the allegations.
In 1993, the US Food and Drug Administration approved Risperdal for treating schizophrenia and bipolar mania in adults. It was only in 2006 that it was approved for treating irritability associated with autism in children.
The company separately agreed in 2013 to pay $2.2 billion to settle US criminal and civil probes into its marketing of Risperdal and two other drugs.
In May, the US Supreme Court rejected J&J's bid to overturn a $70 million jury verdict against it for its failure to warn about risks associated with using Risperdal.
